Jordi Giralt LÃ³pez de Sagredo

List of Publications by Year
in descending order

83 papers	14,027 citations	185998 28 h-index	95083 68 g-index
86 all docs	86 docs citations	86 times ranked	12385 citing authors

#	Article	IF	Citations
1	Randomized Phase 2 Trial of a Novel Clonidine Mucoadhesive Buccal Tablet for the Amelioration of Oral Mucositis in Patients Treated With Concomitant Chemoradiation Therapy for Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 106, 320-328.	0.4	15
2	Selection of lymph node target volumes for definitive head and neck radiation therapy: a 2019 Update. Radiotherapy and Oncology, 2019, 134, 1-9.	0.3	132
3	Radiotherapy practice for paediatric brain tumours across Europe and quality assurance initiatives: Current situation, international survey and future perspectives. European Journal of Cancer, 2019, 114, 36-46.	1.3	12
4	Does ITV vaginal procedure ensure dosimetric coverage during IMRT of post-operative gynaecological tumours without instructions concerning rectal filling?. Reports of Practical Oncology and Radiotherapy, 2018, 23, 136-142.	0.3	0
5	Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiotherapy and Oncology, 2018, 126, 3-24.	0.3	244
6	A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients. Targeted Oncology, 2018, 13, 69-78.	1.7	0
7	GEORCC recommendations on target volumes in radiotherapy for Head Neck Cancer of Unkown Primary. Critical Reviews in Oncology/Hematology, 2018, 130, 51-59.	2.0	13
8	New and safe experimental model of radiation-induced neurovascular histological changes for microsurgical research. Laboratory Animals, 2017, 51, 124-137.	0.5	0
9	Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 1). Oral Oncology, 2017, 70, 58-64.	0.8	20
10	Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 2). Oral Oncology, 2017, 70, 65-72.	0.8	8
11	Quality assurance of radiotherapy in the ongoing EORTC 1219-DAHANCA-29 trial for HPV/p16 negative squamous cell carcinoma of the head and neck: Results of the benchmark case procedure. Radiotherapy and Oncology, 2017, 123, 424-430.	0.3	16
12	p16, HPV, and Cetuximab: What Is the Evidence?. Oncologist, 2017, 22, 811-822.	1.9	19
13	A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (â‰16Âyears) low grade gliomaÂâ€“ A final report. European Journal of Cancer, 2017, 81, 206-225.	1.3	104
14	Fat grafting is a feasible technique for the sequelae of head and neck cancer treatment. Journal of Cranio-Maxillo-Facial Surgery, 2017, 45, 93-98.	0.7	28
15	Effectiveness of radiotherapy for metastatic spinal cord compression in patients with short life expectancy. Reports of Practical Oncology and Radiotherapy, 2017, 22, 58-63.	0.3	4
16	Impact of early trials in molecularly-characterized patients (pts) with head and neck cancer (HNC).. Journal of Clinical Oncology, 2017, 35, 6031-6031.	0.8	1
17	Cetuximab and Radiotherapy in Laryngeal Preservation for Cancers of the Larynx and Hypopharynx. JAMA Otolaryngology - Head and Neck Surgery, 2016, 142, 842.	1.2	40
18	Hypofractionated 3D radiotherapy for inoperable T1-3 N0-1 non-small-cell lung cancer. British Journal of Radiology, 2016, 89, 20150824.	1.0	0

#	Article	IF	Citations
19	Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial. European Journal of Cancer, 2016, 64, 1-11.	1.3	26
20	Estudio comparativo en la definiciÃ³n del volumen de tratamiento en radioterapia con Â«Slow TC ScanÂ» vs. 4D PET/TC Scan en estadios iniciales de cÃ¡ncer de pulmÃ³n de cÃ©lula no pequeÃ±a. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2016, 35, 373-378.	0.0	1
21	Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab. Journal of Clinical Oncology, 2016, 34, 1300-1308.	0.8	190
22	Impact of molecular prescreening for genomically-guided trials in head and neck cancer (HNC).. Journal of Clinical Oncology, 2016, 34, 6030-6030.	0.8	1
23	2820 Association of p16 status and feeding tube use in patients with locoregionally advanced squamous cell cancer of the head and neck treated with radiotherapy +/- cetuximab in a phase III study. European Journal of Cancer, 2015, 51, S564-S565.	1.3	0
24	Compliance and Patient Acceptability of Clonidine Mucoadhesive Buccal Tablet (Clonidine Lauriad) to Prevent Severe Radiomucositis in Head and Neck Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2015, 93, S213.	0.4	0
25	Bernese Periacetabular Osteotomy in a Hip Extra-Articular Resection Followed by Reconstruction Using an Extracorporeal Irradiated Acetabulum Autograft with Megaprosthesis, for Proximal Femur Osteosarcoma in a Pediatric Patient. Case Reports in Medicine, 2015, 2015, 1-5.	0.3	4
26	Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. Lancet Oncology, The, 2015, 16, 221-232.	5.1	153
27	Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. Lancet Oncology, The, 2015, 16, 208-220.	5.1	161
28	Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial. International Journal of Radiation Oncology Biology Physics, 2015, 93, 303-312.	0.4	21
29	Mucoadhesive clonidine (Clonidine Lauriad) in the prevention of severe radiomucositis in head and neck cancer patients: A phase II randomized trial.. Journal of Clinical Oncology, 2015, 33, 6058-6058.	0.8	5
30	Association of Human Papillomavirus (Hpv) and P16 Status with Efficacy and Safety Data in the Phase III Radiotherapy (Rt)/Cetuximab (Cet) Registration Trial for Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (Lascchn). Annals of Oncology, 2014, 25, iv343.	0.6	2
31	RAS mutations and cetuximab in locally advanced rectal cancer: Results of the EXPERT-C trial. European Journal of Cancer, 2014, 50, 1430-1436.	1.3	29
32	Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncology, The, 2014, 15, 184-190.	5.1	611
33	Impact of p16 status on the results of the phase III cetuximab (cet)/radiotherapy (RT).. Journal of Clinical Oncology, 2014, 32, 6001-6001.	0.8	25
34	Targeting CD44high/ID1+ Patient Glioma Initiating Cells by TGFÎ² Receptor I Inhibitor Could Radiosensitize Glioblastoma. International Journal of Radiation Oncology Biology Physics, 2013, 87, S650.	0.4	0
35	Rupatadine oral solution in children with persistent allergic rhinitis: A randomized, doubleâ€blind, placeboâ€controlled study. Pediatric Allergy and Immunology, 2013, 24, 144-150.	1.1	24
36	Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer. BMC Cancer, 2013, 13, 84.	1.1	113

#	Article	IF	Citations
37	Bio-radiation dermatitis: the need of a new grading: in regard to Bernier et al: Ann Oncol 2011; 22(10): 2191â€“2200. Annals of Oncology, 2013, 24, 2463-2465.	0.6	13
38	Constitutive HER2 Signaling Promotes Breast Cancer Metastasis through Cellular Senescence. Cancer Research, 2013, 73, 450-458.	0.4	76
39	Hyperfractionated Versus Conventional Radiotherapy Followed by Chemotherapy in Standard-Risk Medulloblastoma: Results From the Randomized Multicenter HIT-SIOP PNET 4 Trial. Journal of Clinical Oncology, 2012, 30, 3187-3193.	0.8	270
40	Dose variations in tumor volumes and organs at risk during IMRT for headâ€andâ€neck cancer. Journal of Applied Clinical Medical Physics, 2012, 13, 101-111.	0.8	41
41	A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN).. Journal of Clinical Oncology, 2012, 30, 5502-5502.	0.8	18
42	Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2011, 67, 75-82.	1.1	3
43	Palifermin Decreases Severe Oral Mucositis of Patients Undergoing Postoperative Radiochemotherapy for Head and Neck Cancer: A Randomized, Placebo-Controlled Trial. Journal of Clinical Oncology, 2011, 29, 2815-2820.	0.8	148
44	Perioperative treatment for locally advanced rectal carcinoma (LARC) in elderly patients: Evaluation of compliance, tolerability, and outcome in a Spanish referral institution.. Journal of Clinical Oncology, 2011, 29, e19650-e19650.	0.8	0
45	Evidence in medulloblastomas. Clinical and Translational Oncology, 2010, 12, 271-277.	1.2	4
46	Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group. Journal of Clinical Oncology, 2010, 28, 2989-2995.	0.8	339
47	Management of squamous cell carcinoma of the head and neck: updated European treatment recommendations. Expert Review of Anticancer Therapy, 2010, 10, 339-344.	1.1	26
48	Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncology, The, 2010, 11, 21-28.	5.1	1,773
49	Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02. Journal of Clinical Oncology, 2010, 28, 2996-3001.	0.8	683
50	BRCA1 mRNA expression and response in locally advanced esophageal cancer patients (p) treated with chemoradiotherapy.. Journal of Clinical Oncology, 2010, 28, e14573-e14573.	0.8	0
51	Management of Painful Chronic Pancreatitis With Single-Dose Radiotherapy. American Journal of Gastroenterology, 2009, 104, 349-355.	0.2	27
52	QOL for Advanced Squamous Cell Carcinoma of the Head and Neck: Results of a Phase III Randomized Trial of Tirapazamine, Cisplatin, and Radiation vs. Cisplatin and Radiation (TROG 02.02). International Journal of Radiation Oncology Biology Physics, 2009, 75, S30-S31.	0.4	0
53	Phase II Trial of Preoperative Irinotecanâ€“Cisplatin Followed by Concurrent Irinotecanâ€“Cisplatin and Radiotherapy for Resectable Locally Advanced Gastric and Esophagogastric Junction Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1430-1436.	0.4	34
54	Overexpression of Phosphorylated 4E-BP1 Predicts for Tumor Recurrence and Reduced Survival in Cervical Carcinoma Treated With Postoperative Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1316-1322.	0.4	22

#	Article	IF	Citations
55	2053 Does electronic portal image device really impact set-up practice? A first step introducing a displacement correction protocol and PTV margin re-design. European Journal of Cancer, Supplement, 2009, 7, 166.	2.2	0
56	Faecal DNA and calprotectin as biomarkers of acute intestinal toxicity in patients undergoing pelvic radiotherapy. Alimentary Pharmacology and Therapeutics, 2009, 30, 175-185.	1.9	17
57	Effects of Probiotic Lactobacillus Casei DN-114 001 in Prevention of Radiation-Induced Diarrhea: Results From Multicenter, Randomized, Placebo-Controlled Nutritional Trial. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1213-1219.	0.4	134
58	Differential Activation of Protein Translation is Associated with Aggressive Phenotype of Cervical Cancers. International Journal of Radiation Oncology Biology Physics, 2008, 72, S362.	0.4	0
59	Pre-operative chemoradiotherapy with UFT and Leucovorin in patients with advanced rectal cancer: A phase II study. Radiotherapy and Oncology, 2008, 89, 263-269.	0.3	13
60	The Gut Microbiota Predispose to the Pathophysiology of Acute Postradiotherapy Diarrhea. American Journal of Gastroenterology, 2008, 103, 1754-1761.	0.2	154
61	Controversies surrounding the use of neoadjuvant chemotherapy in locally advanced head and neck cancer. Expert Review of Anticancer Therapy, 2008, 8, 1359-1363.	1.1	1
62	Optimizing approaches to head and neck cancer: strengths and weaknesses in multidisciplinary treatments of locally advanced disease. Annals of Oncology, 2008, 19, vii195-vii199.	0.6	10
63	Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Annals of Oncology, 2008, 19, 142-149.	0.6	190
64	Phase III study of tirapazamine, cisplatin and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck. Journal of Clinical Oncology, 2008, 26, LBA6008-LBA6008.	0.8	23
65	Neoadjuvant chemoradiotherapy (CT-RT) in patients (pts) with stage II-IVA esophageal cancer (EC): Retrospective analysis of a Spanish single institution. Journal of Clinical Oncology, 2008, 26, 15635-15635.	0.8	0
66	Quality of Life in Head and Neck Cancer Patients After Treatment With High-Dose Radiotherapy Alone or in Combination With Cetuximab. Journal of Clinical Oncology, 2007, 25, 2191-2197.	0.8	225
67	5010 ORAL Phosphorylated 4E binding protein 1 (p4EBP1) correlates with pathologic grade and prognosis in cervical cancer treated with surgery and radiation therapy. European Journal of Cancer, Supplement, 2007, 5, 314.	2.2	0
68	Duration of Mucositis and Dysphagia following Radiotherapy (+ Cetuximab) for Locoregionally Advanced Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 69, S137.	0.4	3
69	Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. New England Journal of Medicine, 2006, 354, 567-578.	13.9	4,705
70	2691. International Journal of Radiation Oncology Biology Physics, 2006, 66, S593-S594.	0.4	0
71	1001. International Journal of Radiation Oncology Biology Physics, 2006, 66, S129.	0.4	0
72	2255. International Journal of Radiation Oncology Biology Physics, 2006, 66, S352.	0.4	0

#	Article	IF	Citations
73	2549. International Journal of Radiation Oncology Biology Physics, 2006, 66, S515.	0.4	1
74	Prognostic Significance of Vascular Endothelial Growth Factor and Cyclooxygenase-2 in Patients with Rectal Cancer Treated with Preoperative Radiotherapy. Oncology, 2006, 71, 312-319.	0.9	40
75	The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiotherapy and Oncology, 2005, 74, 101-108.	0.3	139
76	Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer. New England Journal of Medicine, 2004, 350, 1945-1952.	13.9	2,704
77	Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy. International Journal of Radiation Oncology Biology Physics, 2002, 54, 1460-1465.	0.4	89
78	Preoperative induction chemotherapy followed by concurrent chemoradiotherapy in advanced carcinoma of the oral cavity and oropharynx. Cancer, 2000, 89, 939-945.	2.0	36
79	31Phosphorus magnetic resonance spectroscopy in the assessment of head and neck tumors. International Journal of Radiation Oncology Biology Physics, 1998, 40, 309-312.	0.4	14
80	Fluorouracil and High-dose Leucovorin with Radiotherapy as Adjuvant Therapy for Rectal Cancer:Results of a Phase II Study. Acta OncolÃ³gica, 1997, 36, 51-54.	0.8	1
81	Preoperative Simultaneous Chemoradiotherapy in Locally Advanced Cancer of the Oral Cavity and Oropharynx. American Journal of Clinical Oncology: Cancer Clinical Trials, 1997, 20, 97-100.	0.6	12
82	Improving Survival of Medulloblastoma: Results in Two Groups of Patients. Oncology, 1996, 53, 38-42.	0.9	6
83	Malignant Lymphoproliferative Diseases in HIV-Seropositive Patients: A study of 40 cases at a single institution in Spain. Acta OncolÃ³gica, 1995, 34, 75-82.	0.8	6